Impact on Recall Rates Following Implementation of Synthesized 2D Mammography in Digital Breast Tomosynthesis Screening

Zuckerman S, Weinstein S, Synnestvedt M, Korhonen K, McDonald E

Radiological Society of North America 2015 Scientific Assembly and Annual Meeting November 29 - December 4, 2015, Chicago IL.

Objective

The goal of this study was to evaluate a population screened entirely with synthesized 2D digital mammograms using Hologic's C-View™ software plus tomosynthesis (C-View+DBT). Recall rates and recall finding types from the C-View+DBT population were compared to similar historic outcomes from traditional digital mammography plus tomosynthesis screening (DM+DBT).

Materials and Methods

Recall rates and lesion type were compared for 15,571 women screened with DM+DBT during the period from October 1, 2011 to February 28, 2013 and 2,090 women screened with C-View+DBT during the period from January 7th, 2015 to March 20th, 2015.

Findings

The overall recall rate with C-View+DBT was 8.3% compared to 8.8% for DM+DBT (p=0.45). In addition, C-View+DBT screening was not associated with a significant change in the distribution of recalled lesion type. Of particular interest, there was no change in the rate of recall for calcific lesions.

	C-View+DBT	DM+DBT
Overall Recall Rate	8.3%	8.8%
Recall Finding Types		
1. Calcifications	1.6%	1.6%
2. Masses	2.4%	2.7%
3. Asymmetries	3.8%	4.5%
4. Architectural Distortions	1.1%	1.0%
5. Technical Reasons	0.05%	0.2%

Conclusion

This study demonstrated no significant difference in recall rates and lesion types when DM is replaced with C-View generated 2D images for use in combination with DBT. Ongoing data collection will allow comparison of cancer detection rates and PPVs.

hologic.com | info@hologic.com | +1.781.999.7300

Presented by Hologic Medical Education

MED-00184 Rev. 001 (03/16) US © 2016 Hologic Inc., All rights reserved. Hologic and C-View are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to womenshealth@hologic.com.